Concerns & Risks -- 7/10
Valuation at or below CV/industrial peers on forward EBITDA. Negligible China exposure. Multiple
credible catalysts (Off-Highway synergies, defense ramp, truck-cycle inflection). Held from 8-9
by elevated leverage (~4x), EPA 2027 regulatory uncertainty, and a cyclical/macro-dependent
recovery thesis.
Weight: 15%
Fwd EV/EBITDA (Guide)
~9.9x
vs ~16.4x peers | Discounted
China Exposure
Immaterial
Not separately disclosed | Non-issue
Net Debt / EBITDA
~4.0x
Post-acquisition | Elevated
Valuation vs. peers
| Metric | ALSN | CMI | PCAR |
|---|---|---|---|
| EV/EBITDA (FY26E guide) | ~9.9x | ~14.3x | ~18.5x |
| EV/EBITDA (consensus) | ~7.1x | — | — |
| P/E (FY26E) | ~14.0x | Peer avg ~17x | |
ALSN sits below peers on every forward basis. Enterprise value $14.23B.
Catalysts
| Catalyst | Detail |
|---|---|
| Off-Highway synergies $120M run-rate | Benefits begin 2H 2026, full run-rate in "a few years." Exceeding expectations. |
| Adj EBITDA margin to 27-29% | From current 25.7%. Volume recovery + synergies. |
| Defense ramp | +64% YoY Q1, new products (3040/4040 MX, Hanwha K9, BAE). Structural tailwind. |
| NA On-Highway truck cycle inflection | 2H 2026/2027. Cautious optimism, order trends improving. |
| EPA 2027 prebuy | Potential 2H 2026 volume pull-forward. |
| Deleveraging + capital return | Target 2.0x + $1.2B buyback authorization + 7th consecutive dividend raise. |
Regulatory risk
| Risk | Detail |
|---|---|
| EPA 2027 NOx rule | Proceeding with 2027 start but "major changes" coming. Two-sided: could drive prebuy but adds medium-duty cost uncertainty. |
| Tariffs | Hindering end-user purchasing decisions. Broader footprint a mitigant. |
| Middle East | Undetermined impact; supply-chain/energy indirect risk. |
Bull case
Off-Highway integration ahead of plan. Defense structural grower. NA on-highway troughy
(worse-to-better). Discounted to peers. $655M+ adj FCF. Deleveraging + buybacks. Management
calling stock "undervalued."
Bear case
4x leverage with little cushion if truck cycle stays weak into 2027. Legacy organic -4.3% with
medium-duty "extremely soft." Consensus FY26 EBITDA ~$2B vs guide ~$1.44B -- revision risk.
Off-Highway adds European cyclicality. EPA/tariff uncertainty could defer recovery.
Data sourced from Daloopa, company filings, and earnings transcripts.